It’s only a matter of time before 3D bio-printing really takes off. One of the leaders in the space is Organovo, a company who has already been able to 3D print living liver tissue, and has an ultimate goal of 3D printing a functioning liver for transplantation within a human being.
Before we get there though, there are many useful applications to 3D printed living tissue, which can already be used today. One such application is that of drug discovery testing. Every year billions of dollars are spent performing clinical trials on potential new drugs for the market. Many of these trials involve human beings, oftentimes being put at some risk. Liver toxicity testing, in particular, is usually performed using tissue samples from cadavers, meaning it’s not all that easy to obtain such samples. What 3D bio-printing enables researchers to do, is create live human tissue, which can then be used as a test bed to discover any negative reactions a particular drug may have on that tissue. Once scaled up, such a process could make available as much tissue as is needed for research, as well as tissue of extremely high quality.
Organovo has been leading the way in this space. They have been working for years to perfect the 3D printing techniques required to produce high quality tissue, which is able to stay alive over a long period of time. Today, the company announced an agreement with one of the largest pharmaceutical corporations on the planet, Johnson & Johnson. The actual agreement was signed between Organovo and Janssen Research and Development (JRD), a pharmaceutical company of Johnson & Johnson.
Under this agreement, of which the exact terms have not yet been disclosed, the companies will work together to evaluate the use of 3D bio-printed tissue in a drug discovery setting. Just what kind of tissue, and to what extent the testing will be done, is yet to be seen, however, it certainly bodes well for the progress of 3D bio-printing technology. To have a major, globally recognizable, corporation like Johnson & Johnson on board, could push the adoption of this technology, as well as its progress to a whole to level. It is interesting to note that following the release of an 8K filing disclosing this agreement this morning, shares of Organovo are up over 11%.
What will the implications of this agreement be? Let’s hear your opinions in the Organovo/Johnson & Johnson forum thread on 3DPB.com.
You May Also Like
Origin to Begin Shipping New Industrial 3D Printer, the Origin One
Today Origin will begin shipping their new Origin One, an industrial 3D printer which the San Francisco-headquartered company claims is already in high demand internationally. In fact, the developer of...
Interview with Scott Sevcik, VP Aerospace Stratasys, on 3D Printing for Aviation and Space
Out of all the possible industries that are deploying more 3D printers, aerospace is probably the most exciting. By reducing the weight of aircraft components, by iterating more, by integrating...
3D Printing News Briefs: October 14, 2019
In today’s 3D Printing News Briefs, everything is new, new, new! Carbon is announcing a new RPU 130 material, and STERNE Elastomere introduces its antimicrobial silicone 3D printing. Protolabs launches...
Prusa Research Releases Prusa Mini for $349
It is no secret that the entry-level 3D Printer market has been brutal. Creality, MonoPrice, and Anet continue to pump out $200 to $300 i3 clones while many companies have...
View our broad assortment of in house and third party products.